Sector
PharmaceuticalsOpen
₹30.79Prev. Close
₹30.76Turnover(Lac.)
₹2.06Day's High
₹31.5Day's Low
₹29.9952 Week's High
₹44.9652 Week's Low
₹26.1Book Value
₹34.11Face Value
₹10Mkt Cap (₹ Cr.)
30.48P/E
101.6EPS
0.3Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 10 | 9.88 | 8.74 | 8.74 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 23.82 | 21.82 | 19.62 | 18.02 |
Net Worth | 33.82 | 31.7 | 28.36 | 26.76 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 51.35 | 51.33 | 51.79 | 57.48 |
yoy growth (%) | 0.03 | -0.88 | -9.9 | 13.43 |
Raw materials | -42.17 | -42.57 | -43.29 | -46.1 |
As % of sales | 82.12 | 82.93 | 83.59 | 80.19 |
Employee costs | -3.75 | -3.5 | -1.97 | -2.8 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 0.52 | 0.45 | 0.63 | 0.64 |
Depreciation | -1.36 | -1.46 | -2.4 | -2.58 |
Tax paid | -1.01 | -0.12 | -0.31 | -0.48 |
Working capital | 5.74 | 1.76 | 11.4 | -13.41 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0.03 | -0.88 | -9.9 | 13.43 |
Op profit growth | -3.71 | -30.16 | -13.02 | -33.22 |
EBIT growth | -2.55 | -20.71 | -16.11 | -45.68 |
Net profit growth | 899.6 | 1.23 | 103.25 | -90.87 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
---|---|---|---|---|
Gross Sales | 45.24 | 44.92 | 52.08 | 58.96 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 45.24 | 44.92 | 52.08 | 58.96 |
Other Operating Income | 0.01 | 0.01 | 0.01 | 0.1 |
Other Income | 0 | 0 | 0 | 0 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
S Nagi Reddy
Independent Director
K Ramchandra Reddy
Whole Time Director & CFO
Koni Reddy
Independent Director
S. Nagavenkata Hareesh
Whole-time Director
S. Manoj Kumar Reddy
Independent Director
Summela Kasu
Company Sec. & Compli. Officer
Namratha Nagla
Survey No 249 Brahmanapally V,
Hayathnagar M,
Telangana - 501511
Tel: 91-40-24036379
Website: http://www.concorddrugs.in
Email: concorddrugsltd@gmail.com
1-2-285 Domalguda,
Hyderabad - 500 029
Tel: 91-040-27638111/4445
Website: www.aarthiconsultants.com
Email: info@aarthiconsultants.com
Summary
Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenter...
Read More
Reports by Concord Drugs Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.